ScripMerck & Co.’s initial Phase II/III waveLINE-003 data for zilovertamab vedotin (zilo-V) in diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology meeting in Chicago rais
ScripSanofi’s hopes that itepekimab will follow Dupixent onto the list of approved drugs for chronic obstructive pulmonary disease (COPD) have been hit by a mixed set of results from a pair of late-stage t
Pink SheetEngland’s health technology assessment (HTA) institute, NICE, has recommended in favor of making Pfizer’s Hympavzi (marstacimab) available on the National Health Service for preventing severe hemophil
ScripUS/Swiss biotech GlycoEra AG announced a $130m series B financing on 27 May that it says will enable it to advance its first protein-degradation drug candidate through Phase II proof of concept as pre